September 22, 2022 — Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% ...
Cardiogenic Shock
This page includes content on technologies to treat cardiogenic shock, including percutaneous ventricular assist devices (pVAD), intra-aortic balloon pumps (IABP) and extracorporeal membrane oxygenation (ECMO). This condition occurs when the heart can no longer pump enough oxygenated blood to the body. The most common cause of cardiogenic shock is damage to the heart from a severe heart attack. The standard of care for this condition for more than 20 years has a 50 percent survival rate, but improvements have recently been seen in studies using early pVAD intervention prior to percutaneous coronary intervention (PCI). For more information, visit the National Institute of Health (NIH) cardiogenic shock information page.
-
-
September 16, 2022 — Abiomed announced two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) ...
-
March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has ... -
March 22, 2022 – Women are less likely to receive lifesaving treatment for cardiogenic shock than men, according to research presented today at ESC Acute CardioVascular Care 2022, a scientific ...
November 7, 2022 — The immediate use of veno-arterial mechanical circulatory extracorporeal membrane oxygenation (ECMO) ...
November 07, 2022
October 21, 2022
October 20, 2022 — Cardiogenic shock—a life threatening condition when a person’s heart can’t pump enough blood to meet ...
October 20, 2022
September 27, 2022 — Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage ...
September 27, 2022
September 22, 2022 — Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella ...
September 22, 2022
September 20, 2022 — An analysis from the Society of Thoracic Surgeons/American College of Cardiology(STS/ACC) TVT ...
September 20, 2022
September 19, 2022 — Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation ...
September 19, 2022
September 16, 2022 — Abiomed announced two approvals from the U.S. Food and Drug Administration (FDA) related to ...
September 16, 2022
September 2, 2022 — Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients ...
September 02, 2022
June 1, 2022 — Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin ...
June 01, 2022
The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032 ...
May 12, 2022
March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...
March 31, 2022
March 22, 2022 – Women are less likely to receive lifesaving treatment for cardiogenic shock than men, according to ...
March 22, 2022
Srihari Naidu, M.D., FACC, FAHA, FSCAI, is the director of both the cardiac cath labs and Hypertrophic Cardiomyopathy ...
November 16, 2021
Feature | Cardiogenic Shock | By Dave Fornell, Editor
April 29, 2021 — The results of a large, national heart attack study show that patients with cardiogenic shock survived ...
April 29, 2021© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now